Autopsy report · NCT00101062

Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

“study drug unavailable”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year after it had already started.
• Ran for about 1 year 11 months before it stopped.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Medicine and Dentistry of New Jersey

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

celecoxib; letrozole

Sites

1

Countries

United States

Trials that died the same way

• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
  “Study drug no longer available” (91% match in meaning)
• An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants
  “Study medication was no longer available for study” (82% match in meaning)
• Study of Vioxx and Radiation Therapy for Brainstem Glioma
  “Unavailability of study drug.” (81% match in meaning)
• BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
  “Drug unavailable” (81% match in meaning)
• P1101 in Treating Patients With Myelofibrosis
  “Study drug became commercially available” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.